Physician poll finds ultralong-acting regimens and home administration could transform HIV market

Ultralong-acting regimens and home administration could rapidly shift the HIV market away from daily orals as the sector enters its “last cycle of innovation,” according to physicians surveyed by analysts at Jefferies.